SMN1 and retinitis pigmentosa: In vivo gene therapies also include Luxturna, a surgical injection beneath the retina that provide a functioning RPE65 gene via adeno-associated viruses for the treatment of retinitis pigmentosa, and Zolgensma, which delivers a novel SMN gene to motor neuron cells via adeno-associated viruses following a local injection for SMA (4).